SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Esperion Therapeutics, Inc. - ESPR

NEW YORK, May 2, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Esperion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On May 2, 2018, Esperion announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication.  Esperion reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group.  On this news, Esperion's share price fell sharply during intraday trading on May 2, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com 
888-476-6529 ext. 9980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-esperion-therapeutics-inc---espr-300641670.html

SOURCE Pomerantz LLP